AI assistant
Anteris Technologies Global Corp. — Board/Management Information 2016
May 22, 2016
33869_rns_2016-05-22_450ba007-380e-4c37-a574-d60eb29487b5.pdf
Board/Management Information
Open in viewerOpens in your device viewer
==> picture [226 x 82] intentionally omitted <==
Admedus Ltd ABN 35 088 221 078
REGISTERED OFFICE: 26 Harris Road Malaga Western Australia 6090
ASX ANNOUNCEMENT
CHAIRMAN’S LETTER TO SHAREHOLDERS
PO Box 6879 East Perth Western Australia 6892 T +61 (0)8 9266 0100 F +61 (0)8 9266 0199 E [email protected]
Brisbane, Australia 23 May 2016
Attached is a letter from Admedus Limited’s (ASX:AHZ) Chairman, Mr. Wayne Paterson.
Follow us: Twitter: @Admedus Facebook: www.facebook.com/pages/Admedus
For more information, please contact:
Dr Julian Chick | Chief Operating Officer | Admedus Limited Tel: +61 (0)8 9266 0100
Media :
Shevaun Cooper | PR Manager | Admedus Limited Tel: +61 (0) 417 985 599 | Email: [email protected]
Media Europe
FTI Consulting Simon Conway / Victoria Foster Mitchell Tel: +44 (0) 20 3727 1000 [email protected]
US Investor
Rx Communications Group, LLC Melody A. Carey +1 917 322 2571 [email protected]
About Admedus Limited
Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.
Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.
Further information on the company can be found on www.admedus.com
==> picture [595 x 44] intentionally omitted <==
==> picture [170 x 63] intentionally omitted <==
23 May 2016
Dear Shareholders,
I would like to update you on current developments within the Company.
As you are aware, Mr. Rodne has recently resigned and I will be acting as Managing Director until a suitable replacement is appointed. Mr. Rodne will be assisting in the transition of the Managing Director responsibilities until 30 June 2016.
I would like to take this opportunity to thank Mr. Rodne for his efforts over the past decade in building Admedus into a multifaceted award winning health care company.
Admedus’ management and Board of Directors are currently undertaking an intensive review across the Company’s global operations with respect to strategy, operations, finances and capital requirements, to ensure that we are optimising our resources and capitalising on our opportunities. We are seeking to improve short term efficiencies, and ensure we have adequate resources to meet our near term commercial objectives.
Admedus is in transition from “launch” to a more stable phase in its lifecycle whereby we can optimise our commercial model with a view to performance improvements as well as cost rationalisation.
I am very confident that our future prospects and strategic potential will enable us to couple our internal capabilities with multiple stand alone and partnership strategies in the future.
Our long term vision is to ensure we continue to build a stable and efficient global healthcare company with world class research and development capabilities.
I look forward to presenting our progress and the Company’s capital strategy to the market in the near future.
Your Board and management will continue with their combined focus on increasing value for all shareholders.
Yours faithfully
==> picture [93 x 33] intentionally omitted <==
Wayne Paterson Chairman